Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study.

ABSTRACT:

Background

Minority racial and ethnic populations have the highest prevalence of type 2 diabetes mellitus but lower use of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1ra), novel medications that reduce morbidity and mortality. Observed disparities may be due to differences in insurance coverage, which have variable cost-sharing, prior authorization, and formulary restrictions that influence medication access.

Objective

To assess whether racial/ethnic differences in SGLT2i and GLP1ra use differ by payer.

Design

Cross-sectional analysis of 2018 and 2019 Medical Expenditure Panel Survey data.

Participants

Adults ≥ 18 years old with diabetes.

Main measures

We defined insurance as private, Medicare, o

SUBMITTER: Bepo L 

PROVIDER: S-EPMC11576692 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature